Presynaptic LRP4 promotes synapse number and function of excitatory CNS neurons.

Elife

Department of Biology, Howard Hughes Medical Institute, Stanford University, Stanford, United States.

Published: June 2017

Precise coordination of synaptic connections ensures proper information flow within circuits. The activity of presynaptic organizing molecules signaling to downstream pathways is essential for such coordination, though such entities remain incompletely known. We show that LRP4, a conserved transmembrane protein known for its postsynaptic roles, functions presynaptically as an organizing molecule. In the brain, LRP4 localizes to the nerve terminals at or near active zones. Loss of presynaptic LRP4 reduces excitatory (not inhibitory) synapse number, impairs active zone architecture, and abolishes olfactory attraction - the latter of which can be suppressed by reducing presynaptic GABA receptors. LRP4 overexpression increases synapse number in excitatory and inhibitory neurons, suggesting an instructive role and a common downstream synapse addition pathway. Mechanistically, LRP4 functions via the conserved kinase SRPK79D to ensure normal synapse number and behavior. This highlights a presynaptic function for LRP4, enabling deeper understanding of how synapse organization is coordinated.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5469616PMC
http://dx.doi.org/10.7554/eLife.27347DOI Listing

Publication Analysis

Top Keywords

synapse number
16
presynaptic lrp4
8
excitatory inhibitory
8
synapse
6
lrp4
6
presynaptic
5
lrp4 promotes
4
promotes synapse
4
number
4
number function
4

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

Henan Academy of Innovations in Medical Science, Zhengzhou, Henan, China.

Background: Glucagon-like peptide 1 (GLP-1) is a peptide hormone that plays several physiological roles in treating diabetes and in protecting the brain. Recent clinical trials testing 4 different GLP-1 class drugs in phase 2 trials showed a clear correlation between neuroprotection and the ability to cross the BBB. Exenatide and Lixisenatide both showed excellent protective effects in patients Parkinson's disease (PD) and both drugs can readily cross the BBB.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Department of Neurology, Mayo Clinic, Rochester, MN, USA.

Background: Alzheimer's disease (AD) is an age-dependent neurodegenerative disorder with limited treatment options. As it progresses, synapse degeneration is the most important feature contributing to cognitive dysfunction. Mitochondria supply synapses with ATP for neurotransmitter release and vesicle recycling and buffer calcium concentrations.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Amsterdam UMC, Amsterdam, Netherlands.

Background: Irsenontrine (e2027) is a potent and selective PDE9 inhibitor that increases cellular cGMP which is important for glutamatergic synaptic function. Irsenontrine was investigated to improve cognition in Lewy Body Dementia (LBD; DLB and PDD), and recent phase 2 study data suggests that irsenontrine could be more effective in DLB patients without amyloid copathology. Here, we evaluated differential change from baseline levels in proteins associated with cGMP pathway in DLB participants without amyloid co-pathology (DLB A-) compared to DLB participants with amyloid co-pathology (DLB A+).

View Article and Find Full Text PDF

Introduction: Plaques are a hallmark feature of Alzheimer's disease (AD). We found that the loss of mucosal-associated invariant T (MAIT) cells and their antigen-presenting molecule MR1 caused a delay in plaque pathology development in AD mouse models. However, it remains unknown how this axis is impacting dystrophic neurites.

View Article and Find Full Text PDF

Autism spectrum disorder (ASD) is a complex challenge, influenced by genetic and environmental factors. This review focuses on the proteins calbindin (CB), calretinin (CR) and parvalbumin (PV) in the context of ASD, exploring their clinical correlations and providing a deeper understanding of the spectrum. In addition, we seek to understand the role of these proteins in GABAergic regulation and their implication in the pathophysiology of ASD.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!